Hims & Hers Health Inc. (HIMS) experienced a significant intraday surge, with its stock price soaring 5.64% during Monday's trading session. The move marked a notable positive reversal for the telehealth company's shares.

The sharp increase is directly attributed to a newly announced collaboration with pharmaceutical giant Novo Nordisk. Under the agreement, Hims & Hers will offer access to Novo's FDA-approved weight-loss drugs, including Ozempic and Wegovy injections and pills, to U.S. consumers through its platform later this month. Crucially, as part of this deal, Novo Nordisk is dismissing its recent patent infringement lawsuit against Hims & Hers, resolving a legal dispute that had been a significant overhang on the stock.

Analysts viewed the partnership as a strategic positive, noting it provides Hims with legitimate, branded GLP-1 products to offset declining revenue from compounded versions and ends a costly legal battle. The agreement also signals a regulatory tailwind, with the FDA expressing approval that Hims will stop advertising unapproved compounded drugs in favor of FDA-approved alternatives through the new partnership.